01 1Viatris
01 1RIVAROXABAN USP
01 1U.S.A
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2020-04-21
Pay. Date : 2020-03-31
DMF Number : 34226
Submission : 2019-10-15
Status : Active
Type : II
20
Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIVAROXABAN USP, with a corresponding US DMF Number 34226.
Remarkably, this DMF maintains an Active status since its submission on October 15, 2019, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 21, 2020, and payment made on March 31, 2020, indicating their dedication to facilitating drug approvals, Categorized as Type II
